DANIEL E. SOFFER, MD, FACC, FSCAICertification:United States Medical Licensing Examination (USMLE) Step I and II - Passed, 1st Attempt - 1993, Step III - stPassed, 1 Attempt - 1995 1994 Educational Commission for Foreign MedicalGraduates (ECFMG # 0-476-774-5) 1997 Board Certified and Diplomate, American Board ofInternal Medicine (ABIM) 2000 Board Certified and Diplomate, ABIM,Cardiovascular Disease # 179302 2002 Board Certified and Diplomate, ABIM, InterventionalCardiology 2011 Board Certified, Endovascular Medicine, AmericanBoard of Vascular Medicine Present Basic and Advanced Cardiac Life Support (BCLSand ACLS)Licensing: DEA # BS6887294 Michigan License # 4301076758 New York License # 224099-1 North Carolina License # 2002-01311Current Position: Co- Director, Carotid Endovascular Services Intervntional Cardiology Zena and Michael A Wiener Cardiovascular Institute Marie Josee and Henry R. Kravis Center for Cardiovascular Health Mount Sinai Medical Center One Gustave L. Levy Place, Box 1030 New York, NY 10029-6574 Director, Vascular Medicine Laboratory The Mount Sinai Heart and Vascular Center 485 Madison Avenue, New York, NY 10022Previous Position: Associate Director, Fellowship Program Interventional Cardiology, Structural Heart, Endovascular & Carotid Interventions Department of Interventional Cardiology Lenox Hill Heart and Vascular Institute New York, NY 10075 Carolina Heart PA Interventional Cardiology, Structural Heart, Endovascular & Carotid Interventions Pitt County Memorial Hospital Greenville, North Carolina
Current Clinical Associate Professor of MedicineAppointment: Department of Internal Medicine Mount Sinai School of MedicinePrevious Clinical Associate professor of medicineAppointments: Department of Internal Medicine Brody School of Medicine East Carolina University Greenville, North CarolinaPostgraduate Training and Fellowships:9/2000-8/2002 Fellowship (PGY 7-8), Interventional Cardiology, Peripheral and Carotid Interventions, Structural heart, Aortic and Mitral valvuloplasty William Beaumont Hospital, Royal Oak, MI7/1997-6/2000 Fellowship (PGY 4-6), Clinical Cardiology Lenox Hill Hospital, New York, NY7/1995-6/1997 Residency (PGY 2-3), Internal Medicine Lenox Hill Hospital, New York, NY7/1994-6/1995 Internship (PGY 1), Internal Medicine Lenox Hill Hospital, New York, NYMedical Education and Academic Honors:10/1985-4/1993 M.D., Ben Gurion University of the Negev, Beer Sheva, IsraelSummer 1989 Visiting Honorary Student, Cardiothoracic Surgery Üelleval Hospital, Oslo, Norway Summer 1990 Selected Honorary Student, Cardiology and Emergency Medicine Albert Einstein College of Medicine, Bronx, New York 1990 and 1991 Two - Time Recipient, Swiss Foundation Scholarship (Awarded to the top 8 out of 200 students for clinical excellence in medicine) 1991-1992 Thesis: “Changes in Pressure Exerted on the Foot During Pregnancy” Ben Gurion University of the Negev, Beer Sheva, Israel 4/1992-3/1993 Rotating Internship, Chaim Sheba Medical Center, Tel Hashomer, IsraelMilitary Service: First Lieutenant, Medical Corps Israel Defense Forces 1981-1982 Combat Medic and Medic Course Instructor 1983-1984 Medic Course Commander 1984-1985 Chief Instructing Officer, School of Military Medicine
High School Education: 1977-1981 Makif Yahud, Yahud, Israel Major Subjects: Biology and Chemistry Graduated with High HonorsMemberships/Fellowships: 1985-Present CMAS world underwater federation 1997-Present American College of Cardiology – Fellow 2003-present The Society for Cardiac Angiography & Interventions- FellowPrimary Investigator / Sub-investigatorPrimary Investigator, Evaluation of the Cascade Abrazo Analyzer and DTM (Direct Thrombin Monitor) TestCard Bivalirudin (“Abrazo DTM”), Sponsored by Helena Labs.Primary Investigator, ORBIT II Pivotal Trial to Evaluate the Safety and Efficacy of the Diamondback 360°®Orbital Atherectomy System in Treating De Novo, Severely Calcified Coronary Lesions, Sponsored byCardiovascular Systems Inc. (CSI).SUPERB Comparison of the Supera PERipheral System to a Performance Goal derived from BalloonAngioplasty Clinical Trials in the Superficial Femoral Artery, Sponsored by IDEV Technologies, Inc.Choice Carotid Stenting For High Surgical Risk Patients; Evaluating Outcomes Through The CollectIon Of ClinicalEvidenceSapphire WW - STENTING AND ANGIOPLASTY WITH PROTECTION IN PATIENTS AT HIGH-RISK FORENDARTERECTOMY Protocol Number P06-3603Protect Protected Carotid Artery Stenting in Subjects at High Risk for CEAProguard Trial- Protection During Carotid Stenting in High Risk Patients with the TriActive ProGUARD SystemVIVA Trial - VIVEXX™ Carotid Revascularization for High Surgical Risk Patients with Extracranial Carotid ArteryStenosis using the Bard® VIVEXX™ Carotid Stent and Emboshield® Bare Wire™ Rapid Exchange EmbolicProtection SystemMAVERIC III – Medtronic Evaluation of the Medtronic AVE Self-Expanding Carotid Stent System with DistalProtection in the Treatment of Carotid StenosisTracer A Multi-center, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Safety and Efficacyof SCH 530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin ReceptorAntagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA·CER)Zomaxx II ZOMAXX II- Trial-A Randomized, Controlled Trial to Evaluate the Safety and Efficacy of theZomaxx™ Drug Eluting Coronary Stent System as Compared to the Taxus™ Express2™ Paclitaxel-Eluting Stent inde novo Coronary Artery LesionsGravitas Gauging Responsiveness with A VerifyNow assay- Impact on Thrombosis And Safety (GRAVITAS)
Xience XIENCE™ V Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval StudyReform REFORM- Evaluation of Effectiveness and Safety of the Formula™ Balloon-Expandable Stent for RenalArtery StenosisEndeavor SVS A Clinical Evaluation of the Medtronic Endeavor Zotarolimus-Eluting Coronary Stent System in theTreatment of Single De novo Lesions in Small Diameter Native Coronary Arteries (Endeavor SVS)Resolute A Clinical Evaluation of the Medtronic Endeavor® Resolute Zotarolimus-Eluting Coronary Stent System inthe Treatment of De Novo Lesions in Native Coronary Arteries with a Reference Vessel Diameter of 2.25 mm to 4.2mm - The Medtronic RESOLUTE US Clinical TrialRealism EVEREST II Continued Access RegistryIntense Iliac artery treatmeNT with thE iNvatec Scuba cobalt chromium stEnt (INTENSE) StudyLiberte TAXUS Libertē Post-Approval StudySuperb Comparison of the SUpera® PERipheral System to a Performance Goal derived from Balloon AngioplastyClinical Trials in the Superficial Femoral Artery (The SUPERB Study)Dapt A prospective, multi-center, randomized, double-blind trial to assess the effectiveness and safety of 12 versus30 months of dual antiplatelet therapy (DAPT) in subjects undergoing percutaneous coronary intervention (PCI) witheither drug-eluting stent (DES) or bare metal stent (BMS) placement for the treatment of coronary artery lesions.FREEDOM Trial – Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management ofMultivessel DiseaseDELTA MI Trial – Direct Inhibition of Protein Kinase C Enzyme to Limit Total Infarct Size in Acute MyocardialInfarctionPREMIUM Trial- Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjectswith Migrane and Patent Foramen Ovale Using the AMPLATZER PFO Occluder Compared to Medical ManagementAMEthyst Trial – A Prospective, Multicenter, Randomized Study to Evaluate the Safety and Efficacy of theInterceptor Embolic Protection Device During Transluminal Percutaneous Coronary Interventions on SaphenousGraftsEVENT Registry- A Multicenter Registry for the Evaluation of Drug Eluting Stents and Ischemic EventsDYNAMIC Registry- Dynamic Evaluation of Percutaneous InterventionASPIRE Trial- Angioplasty in SVG’s with Post Intervention Removal of Embolic DebrisZILVER Trial – Evaluation of the Zilver® PTX™ Vascular Stent in the Above-the-Knee Femoropopliteal Artery Clinical Study Protocol: Phase ISIRIUS Trial - A Multicenter, Randomized, Double-Blind study of the SIROLIMUS Coated Bx VELOCITY Stentin the Treatment of Patients with de-novo Coronary Artery LesionsCARDIOSEAL Septal Occlusion System Registry
TRAP Vascular Filtration System Trial – Randomized Study of TRAP Filter Device in Saphenous Vein GraftPTCA/StentingA Phase II Randomized Multicenter Clinical Study To Evaluate the Safety and Efficacy of the TandemHeartpVAD System vs. Conventional Therapy for Treatment of Cardiogenic ShockTherOx AO System AMIHOT Trial – Acute Myocardial Infarction with Hyperoxemic TherapyFIRE Trial- Distal Protection with BSC/EPI Filterwire vs. PercuSurge Guardwire During SVG StentingCOOL-MI Trial - Hypothermia as an Adjunctive Therapy to PTCA in Patients with Acute MIBARRICADE Trial – PCI with the JOMED PTFE Covered Stent in Degenerated Saphenous Vein GraftsPublications & Presentations: Carotid Artery Stenting in Elderly Patients: Importance of Case Selection Cathet Cardiovasc Intervent 2008;72:318-324 Paul T.L. Chiam, Gary S. Roubin,Sriram S. Iyer, Richard M. Green, Daniel E. Soffer, Christina Brennan, Jiri J. Vitek Prospective Evaluation of Aggressive Medical Therapy for Atherosclerotic renal artery stenosis, with Renal Artery Stenting Reserved for Previously Injured Heart, Brain, or Kidney Hanzel G, Balon H, Wong D, Soffer D, Lee DT, Safian RD Am J Cardiol. 2005 Nov 1;96(9):1322-7 Epub 2005 Sep 1 Impact of Angina Class on Inhibition of Platelet Aggregation Following Clopidogrel Loading in Patients Undergoing Coronary Intervention: Do We Need More Aggressive Dosing Regimens in Unstable Angina? Cathet Cardiovasc Intervent 2003;59:21-25 Daniel Soffer1, Issam Moussa2, Kishore J. Harjai1, Judith Boura1, Simon R. Dixon1, Cindy L. Grines1, William W. O’Neill1 , Gary S. Roubin2, Jeffrey W. Moses2, William Beaumont Hospital, Royal Oak, MI; Lenox Hill Heart and Vascular Institute, New York, NY, USA Sub-Optimal Inhibition of Platelet Aggregation Following Tirofiban Bolus in Patients Undergoing Coronary Intervention for Unstable Angina Pectoris Am J Cardiol 2003;91:872-875 Daniel Soffer1, Issam Moussa2, Murat Karatepe2, Kishore J. Harjai1, Judith Boura1, Simon R. Dixon1, Cindy L. Grines1, William W. O’Neill 1, Gary S. Roubin2 Jeffrey W. Moses2 William Beaumont Hospital, Royal Oak, MI; Lenox Hill Heart and Vascular Institute, New York, NY, USA Images in cardiology: postpartum intramural hematoma-evaluation by computed tomographic angiography. J Clin Hypertens (Greenwich). 2009 Nov;11(11):656. Haden G, Polenta S, Jelnin V, Soffer D, Hecht H.
Platelet Aggregtion Inhibition in Patients Receiving Statins Either Fully or Partially Metabolized by CYP3A4Polena S, Gupta MP, Shaikh H, Zazzali K, Coplan N, Gintnutas J, Labana SS, Soffer DProc West Pharmacol Soc. 2008;51:60-2Renal Stenting Preserves Single Kidney GFR and Renal Mass Compared to MedicalTherapy in Patients with Renal Artery Stenosis: 17 Months Follow-upPresented at the Transcatheter and Cardiovascular Therapeutics, Washington DC, 2002Daniel Soffer, Daniel T. Lee, Helena Balon, Staci Barnhart, Judith A. Boura, Simon R. Dixon,William W. O’Neill, Robert D. SafianWilliam Beaumont Hospital, Royal Oak, MIInter-assay Variability in the Degree of Platelet Inhibition Following GPIIb/IIIa ReceptorBlockade in Patients Undergoing Coronary Intervention: A Comparison of ThreeDifferent Point-of-Care Assays.Presented at the 51th annual session of the American College of Cardiology, 2002Daniel Soffer1, William W. O’Neill1, Kishore J. Harjai1, Judith Boura1, Robert D. Safian1,Cindy Grines1, Issam Moussa2, Gary S. Roubin2, Jeffrey W. Moses2.William Beaumont Hospital, Royal Oak, MI; Lenox Hill Heart and Vascular Institute, NewYork, NY, USAThe Impact of Clinical Presentation on the Degree of Platelet Inhibition at Baseline andfollowing Glycoprotein IIb/IIIa Receptor Blockade in Patients Undergoing PercutaneousCoronary Intervention (abstract)Presented at the 49th annual session of the American College of Cardiology, 2000J Am Coll Cardiol 2000;35, Supp 43A Soffer D, Taviloglu G, New G, Kreps E, Collins M, Iyer S, Roubin G,Moses J, Coplan N, Moussa ILenox Hill Heart and Vascular Institute, New York, NY, USAWhat is the Appropriate Loading Dose of Clopidogrel Prior to Stent Implantation?Insights from a Platelet Inhibition Study (abstract)Presented at the 49th annual session of the American College of Cardiology, 2000J Am Coll Cardiol 2000;35, Supp 307ASoffer D, Taviloglu G, New G, Kreps E, Collins M, Iyer S, Roubin G, Colombo A, Moses J,Coplan N, Moussa ILenox Hill Heart and Vascular Institute, New York, NY, USAIs it Safe to Perform Coronary Intervention in Patients with Occult Blood in Stool andStable Hemoglobin? (abstract)Presented at the 49th annual session of the American College of Cardiology, 2000J Am Coll Cardiol 2000;35, Supp 32ATaviloglu G, Soffer D, New G, Baiocco P, Aboufares A, Glasser L, Zlatanic J, Coplan N,Moses J, Moussa ILenox Hill Heart and Vascular Institute, New York, NY, USA
Does Clinical presentation Impact Platelet Inhibition at Baseline and Following Glycoprotein IIb/IIIa Receptor Blockade in Patents Undergoing Percutaneous Coronary Intervention? (abstract) Presented at the Transcatheter and Cardiovascular Therapeutics, Washington DC, 2000 Karatepe M, Soffer D, Mani A, Taviloglu G, Kreps E, Collins M, Iyer S, Coplan N, Roubin G Lenox Hill Heart and Vascular Institute, New York, NY, USA Clopidogrel Loading Prior to Coronary Stent Implantation, What is the Appropriate Dose? (abstract) Presented at the Transcatheter and Cardiovascular Therapeutics, Washington DC, 2000 Karatepe M, Mani A, Soffer D, Taviloglu G, Kreps E, Collins M, Iyer S, Glasser L, Coplan N, Roubin G Lenox Hill Heart and Vascular Institute, New York, NY, USA The Relationship Between Creatine Kinase Elevation after Single Vessel Intervention and Long-Term Outcome, Causation or Association? (abstract) Presented at the 73rd scientific sessions of the American Heart Association, 2000 Aboufares A, Lasic Z, Khanna A, Minutillo J, Soffer D, Taviloglu G, Coplan N, Moses J, Moussa I Lenox Hill Heart and Vascular Institute, New York, NY, USAReferences: Available upon request